Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis Publisher

Khoshnood S¹ ; Taki E² ; Sadeghifard N¹ ; Kaviar VH¹ ; Haddadi MH¹ ; Farshadzadeh Z^{3, 4} ; Kouhsari E⁵ ; Goudarzi M⁶ ; Heidary M^{7, 8}

Source: Frontiers in Microbiology Published:2021

Abstract

Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis (MTB) remain a primary global threat to the end of tuberculosis (TB) era. Delamanid (DLM) is a nitro-dihydro-imidazooxazole derivative utilized to treat MDR-TB. DLM has distinct mechanism of action, inhibiting methoxy- and keto-mycolic acid (MA) synthesis through the F420 coenzyme mycobacteria system and generating nitrous oxide. While DLM resistance among MTB strains is uncommon, there are increasing reports in Asia and Europe, and such resistance will prolong the treatment courses of patients infected with MDR-TB. In this review, we address the antimycobacterial properties of DLM, report the global prevalence of DLM resistance, discuss the synergism of DLM with other anti-TB drugs, and evaluate the documented clinical trials to provide new insights into the clinical use of this antibiotic. © Copyright © 2021 Khoshnood, Taki, Sadeghifard, Kaviar, Haddadi, Farshadzadeh, Kouhsari, Goudarzi and Heidary.

Related Docs

View other Related Docs

1. Bedaquiline: Current Status and Future Perspectives, Journal of Global Antimicrobial Resistance (2021)

2. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria, Frontiers in Microbiology (2017)

3. Whole Genome Sequencing Results Associated With Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs Among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis From Iran, Journal of Clinical Medicine (2020)

Experts (# of related papers)

View all Related Experts

Mohammad Mehdi Feizabadi (7)

Mehdi Yaseri (2)

Style	Citing Format
MLA	Khoshnood S, et al.. "Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis." Frontiers in Microbiology, vol. 12, no. , 2021, pp. -.
APA	Khoshnood S, Taki E, Sadeghifard N, Kaviar VH, Haddadi MH, Farshadzadeh Z, Kouhsari E, Goudarzi M, Heidary M (2021). Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis. Frontiers in Microbiology, 12(), -.
Chicago	Khoshnood S, Taki E, Sadeghifard N, Kaviar VH, Haddadi MH, Farshadzadeh Z, Kouhsari E, Goudarzi M, Heidary M. "Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis." Frontiers in Microbiology 12, no. (2021): -.
Harvard	Khoshnood S et al. (2021) 'Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis', Frontiers in Microbiology, 12(), pp. -.
Vancouver	Khoshnood S, Taki E, Sadeghifard N, Kaviar VH, Haddadi MH, Farshadzadeh Z, et al.. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis. Frontiers in Microbiology. 2021;12():-.
BibTex	@article{ author = {Khoshnood S and Taki E and Sadeghifard N and Kaviar VH and Haddadi MH and Farshadzadeh Z and Kouhsari E and Goudarzi M and Heidary M}, title = {Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis}, journal = {Frontiers in Microbiology}, volume = {12}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Khoshnood S AU - Taki E AU - Sadeghifard N AU - Kaviar VH AU - Haddadi MH AU - Farshadzadeh Z AU - Kouhsari E AU - Goudarzi M AU - Heidary M TI - Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis JO - Frontiers in Microbiology VL - 12 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Abstract